There’s still value in the stock market even if shares have rallied nearly 100 percent since their March 2009 lows, said Jeff Layman, CIO of BKD Wealth Advisors.
Layman’s picks include Intel , Teva Pharmaceuticals and JPMorgan .
“There’s a lot of macroeconomic support for [JPMorgan],” Layman told CNBC. “We think the dividend will be higher a year from now, and as long as the economy continues to heal, this company ought to produce earnings that are better than expected.”
In the meantime, Bill Smead, CEO and CIO of Smead Capital Management, said he likes companies that generate “high levels of free cash flow.”
“It appears even the U.S. government is going to quit stimulating and that interest rates are going to rise around the world,” he said. “So we like the pharmaceutical companies.”
Scorecard—What They Said:
- Layman's Previous Appearance on CNBC (Oct. 26, 2010)
- Smead's Previous Appearance on CNBC (Mar. 28, 2011)
More Market Intelligence:
- Small Investors Avoid Stocks, So What Are They Buying?
- 'Buy the Dips'—Recovery Will Continue: Strategist
- Markets Will End Year Higher: Stock Picker
CNBC Data Pages:
Smead owns shares of MYL, BMY and CAB in the Smead Value Fund.
No immediate information was available for Layman or his firm.